Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 51 to 100 of 128 results for urinary incontinence

  1. What is the effectiveness of ultrasound-guided visualisation compared with clinical assessment to identify complications after mesh surgery for stress urinary incontinence or pelvic organ prolapse in women?

    assessment to identify complications after mesh surgery for stress urinary incontinence or pelvic organ prolapse in women? Any...

    Research recommendation
    Published
    21 June 2019

  2. What is the effectiveness of colpocleisis compared with sacrospinous fixation for pelvic organ prolapse in elderly women?

    Source guidance details Comes from guidance Urinary incontinence and pelvic organ prolapse in women: management Number

    Research recommendation
    Published
    21 June 2019

  3. What is the most effective surgical management for women with both stress urinary incontinence and pelvic organ prolapse, including the sequence of interventions?

    the most effective surgical management for women with both stress urinary incontinence and pelvic organ prolapse, including the sequence...

    Research recommendation
    Published
    21 June 2019

  4. What is the long-term effectiveness of bladder wall injection with botulinum toxin type A for overactive bladder in women?

    Source guidance details Comes from guidance Urinary incontinence and pelvic organ prolapse in women: management Number

    Research recommendation
    Published
    21 June 2019

  5. What are the long-term outcomes, including patient satisfaction, from the use of pessaries compared with surgery for pelvic organ prolapse in women?

    Source guidance details Comes from guidance Urinary incontinence and pelvic organ prolapse in women: management Number

    Research recommendation
    Published
    21 June 2019

  6. What is the effectiveness of pain management for women who present with chronic pain 3 months after mesh surgery for stress urinary incontinence or pelvic organ prolapse?

    present with chronic pain 3 months after mesh surgery for stress urinary incontinence or pelvic organ prolapse? Any explanatory notes(if...

    Research recommendation
    Published
    21 June 2019

  7. What are the long-term risks of mesh surgery compared with non-mesh surgery for stress urinary incontinence and pelvic organ prolapse in women?

    long-term risks of mesh surgery compared with non-mesh surgery for stress urinary incontinence and pelvic organ prolapse in women? Any...

    Research recommendation
    Published
    21 June 2019

  8. Urinary incontinence and pelvic organ prolapse in women. Patient decision aid on treating complications from mesh used for stress urinary incontinence – Options for women referred to specialist centres

    specialist centres Treating complications from mesh used for stress urinary incontinence 1 This decision aid is for women who have...

  9. Urinary incontinence and pelvic organ prolapse in women. Patient decision aid on treating complications from mesh used for pelvic organ prolapse – Options for women referred to specialist centres

    mesh was for stress urinary incontinence, see NICE's decision aid on treating complications from mesh used for stress urinary...

  10. Urinary incontinence and pelvic organ prolapse in women. Patient decision aid on surgery for vaginal vault prolapse

    with sutures than after sacrocolpopexy with mesh. These are: stress urinary incontinence (leaking urine, especially during exercise or...

  11. Urinary incontinence and pelvic organ prolapse in women. Patient decision aid on surgery for uterine prolapse

    looked at. They include: : Infections, including vaginal infections and urinary tract infections. : Wound complications, including wound...

  12. Urinary incontinence and pelvic organ prolapse in women. Patient decision aid on surgery for stress urinary incontinence

    Surgery for stress urinary incontinence Patient decision aid ? 1 c NICE 2019. All rights reserved. Subject to Notice of rights. Last...

  13. Radially emitting laser fibre treatment of an anal fistula (HTG505)

    Evidence-based recommendations on radially emitting laser fibre treatment of an anal fistula in adults. This involves applying laser energy to the fistula.

    HealthTech guidance
    Published
    13 March 2019
    View recommendations

    Sections for HTG505

  14. Padeliporfin for untreated localised prostate cancer (TA546)

    Evidence-based recommendations on padeliporfin (Tookad) for untreated, unilateral, low-risk prostate cancer in adults.

    Technology appraisal guidance
    Published
    21 November 2018
    View recommendations

    Sections for TA546

  15. Transurethral water vapour ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia (HTG482)

    Evidence-based recommendations on transurethral water vapour ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia in adults. This involves using heated water vapour to destroy some of the prostate tissue.

    HealthTech guidance
    Published
    21 August 2018
    View recommendations

    Sections for HTG482

  16. Laparoscopic ventral mesh rectopexy for internal rectal prolapse (HTG475)

    Evidence-based recommendations on laparoscopic ventral mesh rectopexy for internal rectal prolapse in adults. This involves using a piece of sterile material (mesh) to attach the rectum to the lower back bone using keyhole surgery.

    HealthTech guidance
    Published
    20 June 2018
    View recommendations

    Sections for HTG475

  17. Prostate artery embolisation for lower urinary tract symptoms caused by benign prostatic hyperplasia (HTG469)

    Evidence-based recommendations on prostate artery embolisation for lower urinary tract symptoms caused by benign prostatic hyperplasia in adults. This involves blocking the blood vessels supplying the prostate with tiny plastic particles.

    HealthTech guidance
    Published
    25 April 2018
    View recommendations

    Sections for HTG469

  18. Autism spectrum disorder in under 19s: recognition, referral and diagnosis (CG128)

    This guideline covers recognising and diagnosing autism spectrum disorder in children and young people from birth up to 19 years. It also covers referral. It aims to improve the experience of children, young people and those who care for them.

    Clinical guideline
    Last updated
    20 December 2017
    View recommendations

    Sections for CG128

  19. Transvaginal mesh repair of anterior or posterior vaginal wall prolapse (HTG456)

    Evidence-based recommendations on transvaginal mesh repair of anterior or posterior vaginal wall prolapse. This involves inserting a mesh to replace tissue that has weakened and caused the pelvic organs to drop down (prolapse) into the vagina.

    HealthTech guidance
    Published
    15 December 2017
    View recommendations

    Sections for HTG456

  20. Cystic fibrosis: diagnosis and management (NG78)

    This guideline covers diagnosing and managing cystic fibrosis. It specifies how to monitor the condition and manage the symptoms to improve quality of life. There are also detailed recommendations on treating the most common infections in people with cystic fibrosis.

    NICE guideline
    Published
    25 October 2017
    View recommendations

    Sections for NG78

  21. Uterine suspension using mesh (including sacrohysteropexy) to repair uterine prolapse (HTG445)

    Evidence-based recommendations on uterine suspension using mesh (including sacrohysteropexy) to repair uterine prolapse in women. This involves attaching mesh from the uterus or cervix either to the bone at the base of the spine or to a ligament in the pelvis to hold the uterus in place.

    HealthTech guidance
    Published
    28 June 2017
    View recommendations

    Sections for HTG445

  22. Sacrocolpopexy using mesh to repair vaginal vault prolapse (HTG444)

    Evidence-based recommendations on sacropolpopexy using mesh to repair vaginal vault prolapse in women. This involves attaching mesh, usually from the top of the vagina to the base of the spine, to support the pelvic organs.

    HealthTech guidance
    Published
    28 June 2017
    View recommendations

    Sections for HTG444

  23. Infracoccygeal sacropexy using mesh to repair uterine prolapse (HTG443)

    Evidence-based recommendations on infracoccygeal sacropexy using mesh to repair uterine prolapse in women. This involves attaching mesh from the buttocks to the top of the vagina to hold the uterus in place.

    HealthTech guidance
    Published
    28 June 2017
    View recommendations

    Sections for HTG443

  24. Infracoccygeal sacropexy using mesh to repair vaginal vault prolapse (HTG442)

    Evidence-based recommendations on infracoccygeal sacropexy using mesh to repair vaginal vault prolapse in women. This involves attaching mesh from the buttocks to the top of the vagina to hold the vagina in place.

    HealthTech guidance
    Published
    28 June 2017
    View recommendations

    Sections for HTG442

  25. Further research into extraurethral (noncircumferential) retropubic adjustable compression devices for stress urinary incontinence in women should include detailed safety outcomes, long-term results and patient-reported outcome measures. NICE may update the guidance on publication of further evidence.

    (noncircumferential) retropubic adjustable compression devices for stress urinary incontinence in women should include detailed safety...

    Research recommendation
    Published
    15 May 2017

  26. Sacrocolpopexy with hysterectomy using mesh to repair uterine prolapse (HTG435)

    Evidence-based recommendations on sacrocolpopexy with hysterectomy using mesh to repair uterine prolapse. This involves attaching mesh from the top of the vagina to the base of the spine to support the pelvic organs after the womb has been removed.

    HealthTech guidance
    Published
    22 March 2017
    View recommendations

    Sections for HTG435

  27. Extraurethral (non-circumferential) retropubic adjustable compression devices for stress urinary incontinence in women (HTG434)

    Evidence-based recommendations on extraurethral (non-circumferential) retropubic adjustable compression devices for stress urinary incontinence in women. This involves putting 2 small balloons on either side of the tube that carries urine from the bladder to support it and reduce leaks.

    HealthTech guidance
    Published
    22 March 2017
    View recommendations

    Sections for HTG434

  28. Cerebral palsy in under 25s: assessment and management (NG62)

    This guideline covers diagnosing, assessing and managing cerebral palsy in children and young people from birth up to their 25th birthday. It aims to make sure they get the care and treatment they need for the developmental and clinical comorbidities associated with cerebral palsy, so that they can be as active and independent as possible.

    NICE guideline
    Published
    25 January 2017
    View recommendations

    Sections for NG62

  29. Single-incision short sling mesh insertion for stress urinary incontinence in women (HTG419)

    Evidence-based recommendations on single-incision short sling mesh insertion for stress urinary incontinence in women. This involves putting 2 short slings around the tube that carries urine from the bladder to support it.

    HealthTech guidance
    Published
    12 October 2016
    View recommendations

    Sections for HTG419

  30. Secca System for faecal incontinence (MIB66)

    NICE has developed a medtech innovation briefing (MIB) on the Secca System for faecal incontinence

    Medtech innovation briefing
    Published
    24 May 2016

  31. BladderScan BVI 9400 3D portable ultrasound scanner for measuring bladder volume (MIB50)

    NICE has developed a medtech innovation briefing (MIB) on the BladderScan BVI 9400 3D portable ultrasound scanner for measuring bladder volume

    Medtech innovation briefing
    Published
    22 January 2016

  32. Bladder management strategies:- What are the long-term risks and effects on quality of life of different bladder management strategies for lower urinary tract dysfunction in people with neurological disease?

    on quality of life of different bladder management strategies for lower urinary tract dysfunction in people with neurological disease?...

    Research recommendation
    Published
    9 June 2015

  33. Safety and efficacy of antimuscarinics:- What is the safety and efficacy of more recently developed antimuscarinics compared with (a) placebo/usual care and (b) other antimuscarinics in the treatment of neurogenic lower urinary tract dysfunction?

    care and (b) other antimuscarinics in the treatment of neurogenic lower urinary tract dysfunction? Any explanatory notes(if applicable)...

    Research recommendation
    Published
    9 June 2015

  34. Safety and efficacy of botulinum toxin:- What is the safety and efficacy of botulinum toxin compared with (a) usual care, (b) antimuscarinics and (c) augmentation cystoplasty in people with neurogenic lower urinary tract dysfunction?

    antimuscarinics and (c) augmentation cystoplasty in people with neurogenic lower urinary tract dysfunction? Any explanatory notes(if...

    Research recommendation
    Published
    9 June 2015

  35. What is the safety and efficacy of botulinum toxin compared with (a) usual care, (b) antimuscarinics and (c) augmentation cystoplasty in people with primary cerebral conditions with lower urinary tract dysfunction?

    augmentation cystoplasty in people with primary cerebral conditions with lower urinary tract dysfunction? Any explanatory notes(if...

    Research recommendation
    Published
    9 June 2015

  36. Management strategies to reduce the risk of symptomatic urinary tract infections:- In people with neurogenic lower urinary tract dysfunction, which management strategies (including the use of prophylactic antibiotics and various invasive and non-invasive techniques to aid bladder drainage) reduce the risk of symptomatic urinary tract infections?

    strategies to reduce the risk of symptomatic urinary tract infections:- In people with neurogenic lower urinary tract...

    Research recommendation
    Published
    9 June 2015

  37. Lower urinary tract symptoms in men: management (CG97)

    This guideline covers managing lower urinary tract symptoms (LUTS) in men over 18. It aims to improve the quality of life for men with LUTS by recommending which assessments they should receive, and when conservative management, drug treatment and surgery can help.

    Clinical guideline
    Last updated
    3 June 2015
    View recommendations

    Sections for CG97

  38. Faecal incontinence in adults (QS54)

    This quality standard covers managing faecal (bowel) incontinence in adults (aged 18 and over) in the community (at home and in care homes) and in all hospital departments. It includes assessment of bowel control problems, advice and support, and treatment options. It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    6 February 2014
    View quality statements

    Sections for QS54

  39. Insertion of prostatic urethral lift implants to treat lower urinary tract symptoms secondary to benign prostatic hyperplasia (HTG329)

    Evidence-based recommendations on insertion of prostatic urethral lift implants to treat lower urinary tract symptoms secondary to benign prostatic hyperplasia. This involves pulling back the parts of the prostate that are pressing on the urethra so that it's no longer blocked.

    HealthTech guidance
    Published
    23 January 2014
    View recommendations

    Sections for HTG329

  40. Autism (QS51)

    This quality standard covers health and social care services for adults, young people and children with autism. It includes assessment and diagnosis of autism spectrum disorders, and care and support for people diagnosed with an autism spectrum disorder. It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    21 January 2014
    View quality statements

    Sections for QS51

  41. Mental wellbeing of older people in care homes (QS50)

    This quality standard covers the mental wellbeing of older people (aged 65 and over) receiving care in care homes (including residential and nursing accommodation, day care and respite care). It focuses on support for people to improve their mental wellbeing so that they can stay as well and independent as possible. It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    12 December 2013
    View quality statements

    Sections for QS50

  42. Lower urinary tract symptoms in men (QS45)

    This quality standard covers diagnosing and managing lower urinary tract symptoms in men (aged 18 and over). It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    18 September 2013
    View quality statements

    Sections for QS45

  43. Mirabegron for treating symptoms of overactive bladder (TA290)

    Evidence-based recommendations on mirabegron (Betmiga) for treating overactive bladder in adults.

    Technology appraisal guidance
    Published
    26 June 2013
    View recommendations

    Sections for TA290

  44. Focal therapy using cryoablation for localised prostate cancer (HTG284)

    Evidence-based recommendations on focal therapy using cryoablation for localised stage prostate cancer. This involves using freezing (cryotherapy) needles to find and destroy only the cancerous part of the prostate.

    HealthTech guidance
    Published
    26 April 2012
    View recommendations

    Sections for HTG284

  45. Magnetic resonance image-guided transcutaneous focused ultrasound for uterine fibroids (HTG277)

    Evidence-based recommendations on magnetic resonance image-guided transcutaneous focused ultrasound for uterine fibroids. This involves using magnetic resonance imaging (MRI) to locate the fibroids and direct high-intensity ultrasound energy to destroy fibroid tissue.

    HealthTech guidance
    Published
    23 November 2011
    View recommendations

    Sections for HTG277

  46. Uterine artery embolisation for fibroids (HTG240)

    Evidence-based recommendations on uterine artery embolisation for fibroids. This involves injecting small particles into the blood vessels that take blood to the uterus, via the groin.

    HealthTech guidance
    Published
    24 November 2010
    View recommendations

    Sections for HTG240

  47. Percutaneous posterior tibial nerve stimulation for overactive bladder syndrome (HTG235)

    Evidence-based recommendations on percutaneous posterior tibial nerve stimulation for overactive bladder syndrome. This involves inserting a fine needle into a nerve just above the ankle and passing a mild electric current to the nerves that control bladder function.

    HealthTech guidance
    Published
    27 October 2010
    View recommendations

    Sections for HTG235

  48. Laparoscopic augmentation cystoplasty (including clam cystoplasty) (HTG207)

    Evidence-based recommendations on Laparoscopic augmentation cystoplasty (including clam cystoplasty). This involves sewing or stapling a tissue graft from a section of the small intestine (ileum), colon or other substitutes to the urinary bladder.

    HealthTech guidance
    Published
    16 December 2009
    View recommendations

    Sections for HTG207

  49. Laparoscopic prostatectomy for benign prostatic obstruction (HTG176)

    Evidence-based recommendations on laparoscopic prostatectomy for benign prostatic obstruction. This involves removing the prostate through small cuts in the abdomen, using a fine telescope to see inside the body (keyhole surgery).

    HealthTech guidance
    Published
    26 November 2008
    View recommendations

    Sections for HTG176

  50. Lumbar infusion test for the investigation of normal pressure hydrocephalus (HTG169)

    Evidence-based recommendations on the lumbar infusion test for the investigation of normal pressure hydrocephalus. This involves inserting a lumbar needle into the spinal sac, recording the pressure of the CSF as fluid is infused into the sac.

    HealthTech guidance
    Published
    25 June 2008
    View recommendations

    Sections for HTG169